Ophthalmic Therapeutic Drugs: Technologies and Global Markets
Report Highlights
- The global ophthalmic therapeutic market was valued at $15.5 billion in 2009, showing a growth rate of more than 2½ times that of the overall pharmaceutical industry. The sector will continue to grow through 2014 to $20.6 billion, a compound annual growth rate (CAGR) of 5.9%.
-
As a segment, glaucoma recorded $5.8 billion in 2009 revenue. Six leading glaucoma products will come off patent before 2012, resulting in a compound annual growth rate (CAGR) of 3.6% and estimated revenues of $6.6 billion in 2014.
- Treatment for wet AMD recorded sales of $2.4 billion in 2009. This sector is projected to grow at a 10% compound annual growth rate (CAGR) through 2014 to reach $3.9 billion.
INTRODUCTION
ANALYST CREDENTIALS
Jackson Highsmith is a life sciences research consultant with more than 16 years of research experience. Jackson has been consulting with specialty pharmaceuticals and large pharmaceutical industry players since 2007. Prior to that, he worked at a large research consultancy, where he focused on in-depth research; he also has worked at a large pharmaceutical company in a wide range of medical therapeutics in early- and mid-stage drug development.
- Examine BCC’s complete catalog of Market Research Reports and place direct orders
- Subscribe to any of BCC’s many industry newsletters
- Read announcements of recently published reports and newly launched newsletters
- Register for BCC’s well-known conferences
- Request additional information on any BCC product
- Take advantage of special offers
Frequently Asked Questions (FAQs)
Report Highlights
-
The U.S. ophthalmic market is worth $9.6 billion in 2006, up from $8.8 billion in 2005. At an average annual growth rate (AAGR) of 7.4%, the market will cross $13.8 billion in 2011.
-
Ophthalmic pharmaceuticals dominated the market throughout the forecast period. In 2006 pharmaceuticals comprised 46.6% of the market and, growing at an AAGR of 6.9%, will be worth more than $6.2 billion and maintain more than 45% of the market in 2011.
-
Contact lenses include both functional and cosmetic lenses. Contact lenses generate approximately $1.9 billion in revenues annually in the United States, accounting for a near 20% of the market.
Report Highlights
-
The 2002 U.S. market for prescription ophthalmic drugs was $2.8 billion, and, rising at an average annual growth rate (AAGR) of 8.6%, will reach $4.5 billion in 2007.
-
Glaucoma treatments accounted for $1.4 billion in 2002 and will grow at an AAGR of 8.2% to more than $2 billion in 2007.
-
Products within the ocular infection and ocular allergy treatment segments follow in market presence, with $500 million and $397.1 million, respectively.
-
Ocular allergy treatment will lead growth with an AAGR of 10% through the period, reaching nearly $640 million